78281-72-8 Nepafenac AKSci X5012
 
 
Loading Please Wait...
  X5012    AKSci Reference Standard
Nepafenac
, >98% (HPLC)
 
2-Amino-3-benzoyl-benzeneacetamide
AHR 9434
AL 6515
more..




IDENTITY
CAS Number:78281-72-8
MDL Number:MFCD08067732
MF:C15H14N2O2
MW:254.28
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:NMR, LCMS, FT-IR, HPLC
Physical Form:Yellow powder
Melting Point:177-181°C
Long-Term Storage:Store long-term at room temperature

BIOLOGICAL INFO
Solubility:DMSO: =5 mg/mL
Application(s):Non-steroidal anti-inflammatory agent

REVIEW

 Nepafenac is a prodrug. After penetrating the cornea, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity.

REFERENCES
[1]Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.
[2] Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84.
[3] Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8.
[4] Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H410

Precautionary Statements
P273; P391; P501


Current as of December 8, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use.
Not for human use.



PubChem